slides · global inventory
Fraud Exposure
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 6,793
Current window 5,401-5,430
Pages 227
Rows per page 30
Framework
5,401-5,430 of 6,793
229
The slide uses a Q&A format to highlight internal concerns regarding trial integrity and the potential for participant bias due to unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
230
The slide uses highlighted text to emphasize key criticisms (soft endpoints, cherry-picking, safety signals).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
231
The slide uses a Q&A transcript format to highlight potential safety data suppression.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
232
The slide uses a Q&A format to highlight potential corporate malfeasance regarding safety data reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
235
The slide uses Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
236
The slide uses a direct quote from an ex-employee to undermine the clinical value proposition of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
239
The slide uses a Q&A format to highlight specific concerns about data collection consistency and physiological noise (edema).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
240
The slide uses a Q&A format to present expert testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
243
The slide uses a Q&A format to validate the primary claim made in the headline.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
247
The slide uses a Q&A transcript format to build a case against the safety of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
248
The slide uses a Q&A transcript format to highlight potential safety concerns and lack of transparency regarding trial outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
251
The slide uses a Q&A format to highlight inconsistencies in clinical trial reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
256
The slide uses direct quotes from a KOL to frame the company's town hall as an 'infomercial' that avoids difficult questions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
259
The slide uses a 'Miller XR' moniker to highlight the perceived over-reliance on a single individual.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
260
The slide uses red boxes to highlight the name 'Jennifer Miller' across different study documents to emphasize her consistent involvement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
265
The slide uses a screenshot of a tweet as primary evidence to expose the subject's promotional behavior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
266
Uses press release excerpts to establish a pattern of behavior or conflict of interest.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
267
The slide uses a combination of narrative text, a screenshot of a YouTube video, and snippets of press articles to build a case of poor judgment or questionable association.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
274
The slide uses a Q&A transcript format to undermine the commercial viability of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
285
The slide uses a Q&A format to present expert opinion as evidence of safety risks.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
289
Uses Q&A format to highlight expert skepticism and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
290
The slide uses a Q&A format to highlight allegations of 'artificial enrollment' and data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
291
Uses direct quotes from a trial investigator to undermine the validity of clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
292
The slide uses a Q&A format to highlight allegations of data manipulation and lack of clinical efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
293
The slide uses direct quotes and Q&A transcripts to undermine the credibility of the drug's launch prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
297
The slide uses Q&A transcripts to undermine the competitive advantage of the Vykat tablet formulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
300
The slide uses a Q&A format to highlight specific quotes from a trial investigator regarding drug safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
301
The slide uses a Q&A format to highlight specific allegations of misconduct regarding clinical trial reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
302
The slide uses a Q&A format to highlight potential misconduct by the company.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
303
The slide uses a Q&A format to highlight alleged unethical behavior by Soleno regarding academic integrity and investigator relations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit